• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

United States-based chemotherapy regimen for Ewing sarcoma is more effective and safer than the standard European regimen

byJessie WillisandTeddy Guo
November 9, 2022
in Chronic Disease, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The United States regimen had greater event-free survival and less associated febrile neutropenia compared to the European regimen.

2. More platelet transfusions were required with the European regimen, but more blood transfusions were required with the US regimen.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Ewing sarcoma is a rare bone and soft tissue cancer that typically occurs in the second decade of life. There is currently no international standard chemotherapy regimen for the disease. This study aimed to evaluate two different chemotherapy regimens, one used mainly in the United States (US) and one in Europe. Participants with confirmed Ewing sarcoma were randomized 1:1 to either the European or US regimen. After three years, event-free survival was higher in the US regimen compared to the European regimen. Additionally, less chemotherapy-associated febrile neutropenia was seen in the US group compared to the European group. Platelet transfusions were required more often in the European group, but blood transfusions were required more in the US group. Limitations of this study include the switch from excluding patients with metastatic disease prior to 2016, but then removing this exclusion criteria after 2016. Nonetheless, this study promotes the US chemotherapy regimen for international standard of chemotherapy treatment for Ewing sarcoma.

Click to read the study in the Lancet

Relevant Reading: Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial

In-Depth [randomized controlled trial]: EURO EWING 2012 (EE2012) was an international multicentre randomized controlled phase 3 trial that enrolled participants between March 21, 2014 and May 1, 2019. Eligible patients were aged 2-49 years with confirmed Ewing sarcoma of the bone or soft tissue, or Ewing-like sarcoma. A total of 640 patients were enrolled and randomized 1:1 to either the European regimen (vincristine, ifosfamide, doxorubicin, and etoposide induction, and consolidation using vincristine, actinomycin D, with ifosfamide or cyclophosphamide, or busulfan and melphalan) or the US regimen (vincristine, ifosfamide, doxorubicin, cyclophosphamide, and etoposide induction, plus ifosfamide and etoposide, and consolidation using vincristine and cyclophosphamide, or vincristine, actinomycin D, and ifosfamide, with busulfan and melphalan). The primary outcome was event-free survival with a median follow-up of surviving patients of 47 months. At 3 years, the event-free survival was 61% for the European regimen and 67% for the US regimen (adjusted Hazard Ratio 0.71 [95% CI 0.55-0.92]). Grade 3-5 febrile neutropenia occurred in 74% of the European group and 58% of the US group. More patients required platelet transfusions in the European group, but more patients required blood transfusions in the US group. In summary, the US regimen (vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide) was more effective and less toxic than the European regimen.

RELATED REPORTS

Adjuvant S-1 increases short-term survival in patients with resected biliary tract cancer

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

Spiritual care reduces fatigue and pain among patients receiving chemotherapy

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: actinomycin DbusulfanchemotherapycyclophosphamidedoxorubicinetoposideEwing sarcomafebrile neutropeniaifosfamidemelphalansarcomasoft tissue malignancySoft Tissue Sarcomavincristine
Previous Post

#VisualAbstract: Timing of daily antihypertensives does not change cardiovascular outcomes

Next Post

Gonadotropin releasing hormone analogues use not associated with increased subsequent gender affirming hormone use

RelatedReports

Fatty liver disease may independently predict high-risk coronary disease
Chronic Disease

Adjuvant S-1 increases short-term survival in patients with resected biliary tract cancer

February 1, 2023
#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
StudyGraphics

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

January 31, 2023
No benefit of erlotinib in combined hepatocellular carcinoma treatment
Oncology

Spiritual care reduces fatigue and pain among patients receiving chemotherapy

January 11, 2023
#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer
StudyGraphics

#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer

October 11, 2022
Next Post
Parental nonmedical prescription opioid use linked to adolescent use

Gonadotropin releasing hormone analogues use not associated with increased subsequent gender affirming hormone use

Improved glycemic control in type 1 diabetics on very low-carbohydrate diets

Wellness Check: Nutrition

#VisualAbstract: Methylprednisolone prophylaxis for cardiac surgery in infants with congenital heart disease does not improve outcomes

#VisualAbstract: Methylprednisolone prophylaxis for cardiac surgery in infants with congenital heart disease does not improve outcomes

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options